A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting.
<h4>Purpose</h4>The purpose of this research was to evaluate the effectiveness and safety of neoadjuvant chemotherapy plus radical surgery (NCRS) and concurrent chemoradiotherapy (CCRT) based on three-dimensional conformal radiation therapy (3DCRT) for FIGO 2018 stage IB3/IIA2 patients w...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0319405 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849736120716230656 |
|---|---|
| author | Renxian Xie Keyan Xie Xiaoluan Lin Yanchen Ji Jianzhou Chen Chuangzhen Chen |
| author_facet | Renxian Xie Keyan Xie Xiaoluan Lin Yanchen Ji Jianzhou Chen Chuangzhen Chen |
| author_sort | Renxian Xie |
| collection | DOAJ |
| description | <h4>Purpose</h4>The purpose of this research was to evaluate the effectiveness and safety of neoadjuvant chemotherapy plus radical surgery (NCRS) and concurrent chemoradiotherapy (CCRT) based on three-dimensional conformal radiation therapy (3DCRT) for FIGO 2018 stage IB3/IIA2 patients with cervical squamous cell carcinoma in a resource-limited setting.<h4>Methods</h4>The clinical outcomes and incidence of complications in 137 patients who underwent NCRS with those of 163 patients who CCRT based on 3DCRT were compared. Propensity score matching (PSM) analysis was used to match the two groups to enable further statistical comparisons. Survival analysis was performed utilizing Cox proportional hazards regression analyses, Kaplan-Meier curves, and log-rank tests. Furthermore, the incidence of complications between the two groups was also compared using chi-squared tests.<h4>Results</h4>PSM analysis identified 103 matched pairs of patients. The NCRS and CCRT groups exhibited 5-year overall survival (OS) rates of 85.4% and 91.2%, respectively (p=0.19). Additionally, the NCRS and CCRT groups exhibited 5-year disease-free survival (DFS) rates of 76.7% and 89.3% (p=0.02), and the recurrence rates were 20.4% and 9.7% (p=0.03), respectively. However, the CCRT group exhibited a higher incidence of early any-grade complications (79.6% vs 35.9%, p<0.001) and early grade 3 complications (15.5% vs 2.9%, p=0.002) compared to the NCRS group. In terms of overall late complications, there was no significant difference in the incidence between the two groups. Multivariate analysis revealed that stage IIA2 emerged as an independent risk factor for OS (aHR 8.89; p=0.033). Moreover, histologic grade 2-3 (aHR 5.3; p=0.022), stage IIA2 (aHR 2.95; p=0.043), NCRS treatment (aHR 2.41; p=0.012) were identified as independent risk factors for DFS.<h4>Conclusion</h4>In resource-limited settings, for patients with FIGO 2018 stage IB3/IIA2 cervical squamous cell carcinoma, 3DCRT-based CCRT offers superior disease-free survival and reduced recurrence rates compared to NCRS, despite increased early complication rates. |
| format | Article |
| id | doaj-art-db52c8a5541343488512dbc0f1626f2d |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-db52c8a5541343488512dbc0f1626f2d2025-08-20T03:07:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01203e031940510.1371/journal.pone.0319405A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting.Renxian XieKeyan XieXiaoluan LinYanchen JiJianzhou ChenChuangzhen Chen<h4>Purpose</h4>The purpose of this research was to evaluate the effectiveness and safety of neoadjuvant chemotherapy plus radical surgery (NCRS) and concurrent chemoradiotherapy (CCRT) based on three-dimensional conformal radiation therapy (3DCRT) for FIGO 2018 stage IB3/IIA2 patients with cervical squamous cell carcinoma in a resource-limited setting.<h4>Methods</h4>The clinical outcomes and incidence of complications in 137 patients who underwent NCRS with those of 163 patients who CCRT based on 3DCRT were compared. Propensity score matching (PSM) analysis was used to match the two groups to enable further statistical comparisons. Survival analysis was performed utilizing Cox proportional hazards regression analyses, Kaplan-Meier curves, and log-rank tests. Furthermore, the incidence of complications between the two groups was also compared using chi-squared tests.<h4>Results</h4>PSM analysis identified 103 matched pairs of patients. The NCRS and CCRT groups exhibited 5-year overall survival (OS) rates of 85.4% and 91.2%, respectively (p=0.19). Additionally, the NCRS and CCRT groups exhibited 5-year disease-free survival (DFS) rates of 76.7% and 89.3% (p=0.02), and the recurrence rates were 20.4% and 9.7% (p=0.03), respectively. However, the CCRT group exhibited a higher incidence of early any-grade complications (79.6% vs 35.9%, p<0.001) and early grade 3 complications (15.5% vs 2.9%, p=0.002) compared to the NCRS group. In terms of overall late complications, there was no significant difference in the incidence between the two groups. Multivariate analysis revealed that stage IIA2 emerged as an independent risk factor for OS (aHR 8.89; p=0.033). Moreover, histologic grade 2-3 (aHR 5.3; p=0.022), stage IIA2 (aHR 2.95; p=0.043), NCRS treatment (aHR 2.41; p=0.012) were identified as independent risk factors for DFS.<h4>Conclusion</h4>In resource-limited settings, for patients with FIGO 2018 stage IB3/IIA2 cervical squamous cell carcinoma, 3DCRT-based CCRT offers superior disease-free survival and reduced recurrence rates compared to NCRS, despite increased early complication rates.https://doi.org/10.1371/journal.pone.0319405 |
| spellingShingle | Renxian Xie Keyan Xie Xiaoluan Lin Yanchen Ji Jianzhou Chen Chuangzhen Chen A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting. PLoS ONE |
| title | A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting. |
| title_full | A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting. |
| title_fullStr | A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting. |
| title_full_unstemmed | A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting. |
| title_short | A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting. |
| title_sort | comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for figo 2018 stage ib3 iia2 cervical squamous cell carcinoma long term efficacy and safety in a resource limited setting |
| url | https://doi.org/10.1371/journal.pone.0319405 |
| work_keys_str_mv | AT renxianxie acomparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT keyanxie acomparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT xiaoluanlin acomparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT yanchenji acomparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT jianzhouchen acomparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT chuangzhenchen acomparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT renxianxie comparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT keyanxie comparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT xiaoluanlin comparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT yanchenji comparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT jianzhouchen comparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting AT chuangzhenchen comparisonofneoadjuvantchemotherapyandconcurrentchemoradiotherapyforforfigo2018stageib3iia2cervicalsquamouscellcarcinomalongtermefficacyandsafetyinaresourcelimitedsetting |